DESIGN, DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF LAGERSTROEMIA SPECIOSA-PHOSPHATIDYLCHOLINE COMPLEX: AS A BUDDING ANTIDIABETIC AGENT

Abstract

Developing the drugs as amphiphilic lipid complexes is a potential approach for improving therapeutic efficacy of the
drugs by increasing solubility, reducing drug crystallinity, modifying dissolution behaviour and improving bioavailability.
Lagerstroemia speciosa (Banaba), plant is a vital source of corosolic acid (2alpha-hydroxyursolic acid), a terpenoid derivative
documented to be responsible for anti-diabetic, anti-inflammatory and antihypertensive activities, exhibited by the plant.
Major limitation associated with this compound is poor solubility and thus the dissolution restrains its bioavailability. To
overcome this limitation, Lagerstroemia speciosa phospholipid complex (HAELS) was developed and subjected to
pharmaceutical investigation by thermal analysis (differential scanning calorimetry), crystallographic (X-ray diffractography), surface morphology (scanning electron microscopy), spectroscopic methods (FT-IR), solubility, and the
dissolution (in vitro drug release) as well as pharmacological evaluation by in vivo Streptozotocin-nicotinamide (STNNCM) induced diabetes model at the dose of 100 mg/kg and 200 mg/kg. The phospholipid complex of Lagerstroemia
speciosa was found, fluffy and porous with rough surface morphology in the SEM. Further, FT-IR, DSC, and XRD data
confirmed the formation of the complex. The improved dissolution was shown by the phospholipid complex. Animal
study data revealed dose dependent antidiabetic and antihypolidemic activities. The phytosome may be considered as
promising drug delivery system for improving the overall absorption and bioavailability of the L. speciosa molecule for the
treatment of diabetes.